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Background: Despite over 50 years of experience with adrenocorticotropic hormone (ACTH) as 
a treatment for acute exacerbations of multiple sclerosis, there have been no trials   examining the 
options of the 2–3-week dosing regimen or intramuscular injection protocol used in the original 
trials. At our clinic, we performed a small, prospective, randomized pilot study to examine the 
efficacy and safety of, and patient satisfaction with, a short (five-day) self-administered ACTH 
dosing protocol for exacerbations of multiple sclerosis, and to compare the subcutaneous and 
intramuscular routes of administration.
Methods: Patients for this study were recruited from an outpatient treatment clinic. Each patient 
self-administered natural ACTH gel 80 U/day by subcutaneous or intramuscular injection for 
five consecutive days and was evaluated at baseline and on days 7 and 14. Patient feedback was 
collected using the Patient Global Impression of Change (PGI-C, the primary efficacy measure), 
a patient global visual analog scale, the Expanded Disability Status Scale, a timed walk, the 
Nine-hole Peg Test, and the Clinical Global Impression of Change.
Results: Of the 20 enrolled patients (mean age 39.5 years), 19 completed the study. On day 
14, 61.1% of patients (11 of 18 with day 14 scores) were treatment responders, and rated their 
condition as “very much improved” or “much improved” on the PGI-C. The intramuscular 
group had numerically more responders, but there was no significant difference in the propor-
tion of responders between the intramuscular and subcutaneous groups at day 14 (P = 0.3). 
The intramuscular route of injection was associated with more injection site pain than the 
subcutaneous route.
Conclusion: A shorter five-day course of intramuscular or subcutaneous ACTH gel may 
improve symptoms associated with acute exacerbations of multiple sclerosis. Larger studies 
with standard of care controls are needed to confirm whether this shorter course of intramuscular 
or subcutaneous ACTH gel is effective and could potentially be substituted for the standard 
14-day treatment.
Keywords: adrenocorticotropic hormone, ACTH, multiple sclerosis, acute exacerbations, 
Acthar Gel, autoimmune diseases
Introduction
Multiple sclerosis is a chronic progressive disease resulting in damage to the myelin 
sheath and nerves of the central nervous system (brain, spinal cord, and optic nerves). 
It is thought to be an autoimmune disorder, is usually diagnosed during early to late Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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adulthood, and affects 2–3 times more women than men.1 
Approximately 350,000 Americans are diagnosed with 
multiple sclerosis,2 although the number may be higher 
because symptoms generally do not appear until the disease 
has progressed.
Symptoms and their severity and duration vary greatly 
among patients. Symptoms may include extreme fatigue, dif-
ficulty with memory and concentration, vision loss, blurred 
or double vision, numbness, tingling, loss of balance and 
coordination, tremors, stiffness, slurred speech, and bladder/
bowel dysfunction.1,2 Multiple sclerosis is rarely fatal, and 
the majority of patients do not become severely disabled. 
The most common form of multiple sclerosis is relapsing-
remitting (85% of patients), where patients experience 
discrete and acute exacerbations or flareups of symptoms, 
followed by partial or complete remission from symptoms 
or disease activity.2
Current treatments for multiple sclerosis include disease-
modifying drugs that reduce the frequency and intensity of 
exacerbations, and drugs that treat the symptoms or the exac-
erbation itself.1,2 The standard treatment for severe exacerba-
tions is a 3–5-day course of intravenous methylprednisolone. 
If intravenous corticosteroids cannot be administered, are 
unavailable, are not effective, or are not well tolerated, 
adrenocorticotropic hormone (ACTH) is recommended as 
an alternative option.2
ACTH has demonstrated efficacy in the treatment of acute 
exacerbations of multiple sclerosis in controlled clinical 
trials, and is approved by the US Food and Drug Admin-
istration for treatment for acute exacerbations of multiple 
sclerosis.3–5 In all trials of ACTH in multiple sclerosis, the 
drug was administered as intramuscular injections for at least 
two weeks.3–5 Based on these trials, the protocol currently 
approved by the Food and Drug Administration prescribes 
daily doses of ACTH ranging from 80 to 120 U, given as 
intramuscular or subcutaneous injections for 14–21 days to 
treat acute exacerbations of multiple sclerosis.6 However, a 
shorter protocol may be effective. One clinical trial of ACTH, 
for example, found symptoms significantly improved com-
pared with placebo after seven days of treatment.4 Similarly, 
methylprednisolone, the standard therapy for treatment of 
exacerbations, was originally given as a longer course of 
treatment before it was reported that a shorter five-day course 
was equally effective.7
In many instances, subcutaneous injections may 
offer a viable route of administration for drugs tradition-
ally administered intramuscularly. It has recently been 
shown that subcutaneous and intramuscular injections of 
ACTH are bioequivalent in stimulating cortisol levels in 
healthy volunteers.8 The subcutaneous injection is easier 
to administer for the following reasons, ie, a larger inject-
able area, no need to identify anatomical landmarks, easier 
to administer in emaciated patients, and a superior safety 
profile.9 Because the gel formulation of natural ACTH has 
been approved to be dosed subcutaneously for acute exacer-
bations of multiple sclerosis and for other indications, and 
shorter courses of treatment are suggested by the literature, 
we conducted a pilot study to test a shorter, self-administered 
five-day injection regimen and to compare the effectiveness, 
safety, and patient satisfaction of these two routes of ACTH 
administration in patients with an acute exacerbation of 
multiple sclerosis.
Materials and methods
Patients
Study participants were men and women aged $18 years 
with a clinical diagnosis of relapsing-remitting, secondary 
progressive, or progressive relapsing multiple sclerosis, who 
presented at an outpatient clinic with an acute exacerbation 
within 24–120 hours of symptom onset. While discussing 
treatment options, participants were given the option to be 
screened for the study by the investigator. Those who chose not 
to participate were given the standard treatment of intravenous 
methylprednisolone. Patients who were on other investigative 
drugs, chemotherapeutic agents, the humanized monoclonal 
antibody, natalizumab (Tysabri®, Biogen Idec, Cambridge, 
MA), or had a history of a clinically significant infection 
within 30 days prior to study entry, were excluded. Women 
who were nursing, pregnant, or planning to become pregnant, 
and those of childbearing potential (ie, those who were not 
postmenopausal for at least one year) who were unwilling to 
use effective contraception were excluded. Concomitant use of 
certain medications (acetylsalicylic acid, anticholinesterases, 
oral anticoagulants, chemotherapeutic agents, cholestyramine, 
systemic corticosteroids, cyclosporine, digitalis glycosides, 
ephedrine, ketoconazole, macrolide antibiotics, phenobarbi-
tal, phenytoin, rifampicin, thalidomide, or vaccines) was not 
permitted during the study. Informed consent was signed and 
collected by either the investigating physician or by staff after 
the patient had the opportunity to learn and ask questions 
about the study. Patients were treated immediately after being 
diagnosed and providing informed consent.
Study design, randomization, and dosing
This was a two-week prospective, randomized, open-
label, single-center, pilot study with two treatment arms Drug Design, Development and Therapy 2011:5
SC Arm
(n = 10)
IM  Arm
(n = 10)
Day 2 SC
injection
(home)
Day 3 SC
injection
(home)
Day 4 SC
injection
(home)
Day 5 SC
injection
(home)
Day 5 IM
injection
(home)
Day 4 IM
injection
(home)
Day 3 IM
injection
(home)
Day 2 IM
injection
(home)
Visit 1
day 1,
baseline and
first injection
Visit 2
day 7 (+/− 1 day),
acute treatment
assessments
Visit 3
day 14 (+/− 1 day),
final disease
assessments
Open-label ACTH gel 80 U/day SC x 5 days
Open-label ACTH gel 80 U/day IM x 5 days
Days
Figure 1 Study design. Study subjects were randomized to self-administer either 80 U of intramuscular AcTh gel or 80 U of subcutaneous AcTh gel daily on days 1–5 
of the study.
Abbreviations: iM, intramuscular; Sc, subcutaneous; AcTh, adrenocorticotropic hormone.
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(see Figure 1). A five-day treatment course was chosen 
because the standard corticosteroid intravenous treatment 
is 3–5 days. The dose of 80 U/day is the lower end of the 
approved dose range for acute exacerbations of multiple 
sclerosis. Since this is a self-administration study, we chose 
the lower dose (80 U/day) because each multiuse vial of 
ACTH holds 80 U/mL in 5 mL gel volume, and we believe 
this offers the most convenient and cost-effective dosing for 
the patient without the need to discard any unused drug at 
the end of treatment.
After clinical evaluation and informed consent was obtained 
at the first visit on day 1, subjects were randomized using a 
random-number generator in a 1:1 scheme to receive ACTH gel 
(HP Acthar® gel [repository corticotrophin injection], Questcor 
Pharmaceuticals, Union City, CA)6 dosed at 80 U/day, given 
as either an intramuscular or subcutaneous injection on days 
1–5 of the study. Participants were trained to self-administer 
the injection by study personnel during the first visit. During 
the study period, ACTH gel injections were the only means of 
treating the exacerbations. The subjects were then reevaluated 
on days 7 and 14. Compliance was evaluated by daily responses 
on the patient treatment performance surveys.
Outcomes
Treatment performance
Both subjective and objective measures of drug response were 
used in the study (Table 1). The primary outcome measure 
was the Patient Global Impression of Change (PGI-C), a self-
administered daily change scale, with scores ranging from 1 
(very much improved) to 7 (very much worse) used to record a 
patient’s impression about the effectiveness of the treatment.10 
The measure of symptom alleviation was the final time point 
score of the PGI-C on day 14; patients reporting change scores 
of 1 and 2 were considered to be treatment responders.
A patient visual analog scale was also used to quan-
tify symptoms associated with their acute exacerbation of 
multiple sclerosis. Each day during the course of the study, 
participants marked a linear scale that ranged from 1 (no acute 
exacerbation of symptoms) to 10 (worst imaginable acute 
exacerbation of symptoms). In addition, we assessed patient 
satisfaction with the self-administration technique using a 
drug attitude questionnaire developed for this study.
The clinical impression of treatment performance with 
intramuscular or subcutaneous ACTH gel was quantified 
using a Clinical Global Impression of Change (CGI-C) 
questionnaire.11 Disability was quantified using the Kurtzke 
Expanded Disability Status Scale (EDSS) at each study visit 
on days 1, 7, and 14.12 Objective measures of drug performance 
included documentation of results of a timed walk13 and the 
Nine-hole Peg Test for finger dexterity,14 which were measured 
pretreatment (on day 1) and on days 7 and 14 after treatment.
Safety
Medical history was elicited, and physical examination, includ-
ing vital signs, was performed on all participants at study Drug Design, Development and Therapy 2011:5
Table 1 Schedule of assessments
Day
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Self-injection x x x x x
Subjective efficacy assessments
  Patient visual analog scale x x x x x x x x x x x x x x
  Pgi-c x x x x x x x x x x x x x
  Drug attitude questionnaire             x             x
Objective efficacy assessments
  cgi-c             x             x
  nine-hole Peg Test x x x
  Timed walk x           x             x
  eDSS x           x             x
Abbreviations: eDSS, expanded Disability Status Scale; cgi-c, clinical global impression of change; Pgi-c, Patient global impression of change.
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entry (day 1) and at the two follow-up visits (days 7 and 14). 
Complete blood counts and urinalysis were performed on all 
three study visits. All adverse events occurring during the 
study period were documented. Serious adverse events were 
classified as those that required inpatient hospitalization, were 
life-threatening, or resulted in significant disability or death.
Data analysis
All participants receiving at least one dose of medication 
were included in the safety analysis; subjects receiving at 
least one dose of study medication and completing one PGI-C 
scale were included in the treatment performance analysis. 
Descriptive statistics were used for treatment performance 
and safety analyses. This study was designed neither with a 
formal hypothesis nor with power calculations.
Results
Study population
A total of 20 patients were enrolled in this pilot study, 
comprising 17 women (85%) and three men (15%). All par-
ticipants were Caucasian, and aged 25–59 (mean 39.5 ± 9.9) 
years. The characteristics of the two groups at baseline were 
similar and are detailed in Table 2.
Treatment performance
PGI-C scores were used to determine the percentage of 
responders versus nonresponders in the intramuscular and 
subcutaneous groups at days 7 and 14 (Figure 2). In both 
groups, the percentage of responders increased between   
days 7 and 14, with 77.7% (7/9) of the intramuscular group 
and 44.4% (4/9) of the subcutaneous group responding by day 
14. Although there were more intramuscular responders at 
days 7 and 14, the final time point scores for the two methods 
were not significantly different (P = 0.335, two-sided Fisher’s 
Exact test, post hoc comparison).
The CGI-C scores were consistent with the PGI-C 
scores (Figure 2). In both the CGI-C and PGI-C assess-
ments, the percentage of responders increased over time. 
Interestingly, the clinician assessment scored more respond-
ers, indicating more symptom improvement than the patient 
assessments.
The raw data scores for the PGI-C and CGI-C assess-
ments are summarized in Tables 3A and 3B. Overall, the 
data indicate an improvement in symptom exacerbation. 
Between days 7 and 14, both intramuscular and subcutane-
ous patients went from “minimally worse” or “much worse” 
to an improved symptom score. By day 14, the clinician 
assessment of “very much improved” or “much improved” 
increased to 100% for the intramuscular patients and 77.7% 
for the subcutaneous patients.
These data show that patients responded to a shorter, five-
day course of treatment, and that although the intramuscular 
route seemed more effective than the subcutaneous route, 
the difference was not statistically significant in this small 
sample.
Table  2  Demographics  and  clinical  neurological  measures  at 
baseline
Parameter Intramuscular  
group (n = 10)
Subcutaneous   
group (n = 10)
Age, mean (SD) 36.1 (8.9) 42.5 (10.3)
gender, n (%)
  Female 7 (70) 10 (100)
  Male 3 (30) 0
race, n (%)
  caucasian 10 (100) 10 (100)
Mean timed  
walk test (seconds)
6.9 7.3
nine-hole Peg Test 14.7 14.5
Visual analog scale 6.3 4.3
eDSS 2.00 2.50
Abbreviations: SD, standard deviation; eDSS, expanded Disability Status Scale.Drug Design, Development and Therapy 2011:5
Table 3A Patient global impression of change scores on days 7 and 14
Study day Very much  
improved*
Much  
improved*
Minimally  
improved
No  
change
Minimally  
worse
Much 
worse
Intramuscular group (n = 10)†
Day 7 10% (1) 50% (5) 20% (2) 10% (1) 10% (1) 0
Day 14 44.4% (4) 33.3% (3) 0 22.2% (2) 0 0
Subcutaneous group (n = 10)‡
Day 7 10% (1) 10% (1) 10% (1) 20% (2) 30% (3) 20% (2)
Day 14 11.1% (1) 33.3% (3) 0 33.3% (3) 11.1% (1) 11.1% (1)
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Figure 2 Percentage of responders as determined by the Patient global impression of change (A) and clinical global impression of change (B) score cards on days 7 and 14. 
Responders were defined by a patient or clinical response of “much improved” or “very much improved.” Both assessments reported a drug response to a five-day treatment 
in both the iM and Sc groups, and an increase in drug response at day 14. 
Abbreviations: cgi, clinical global impression of change; iM, intramuscular; Sc, subcutaneous.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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The visual analog scale data (Figure 3) support the 
PGI-C data showing symptom improvement by day 14 in 
both the intramuscular and subcutaneous treatment groups. 
The intramuscular treatment group showed a numerically 
greater response than the subcutaneous treatment group (+3.8 
units versus +1.4 units, respectively). The final improvement 
scores (day 14) for the two groups were very similar, ie, 2.5 
(intramuscular) and 2.9 (subcutaneous), on a scale of 0–10, 
where 0 = “no exacerbation symptoms” and 10 = “worst 
exacerbation symptoms possible.”
The objective measures of function from a mean timed 
walk and the Nine-hole Peg Test are presented in Table 4. 
There is some improvement seen in the mean timed walk and 
Nine-hole Peg Test scores, although neither was statistically or 
clinically significant. This may be expected, because baseline 
scores (day 1) were already in a highly functional range.
Table 3B clinical global impression of change scores on days 7 and 14
Study day Very much  
improved*
Much  
improved*
Minimally  
improved
No  
change
Minimally  
worse
Much 
worse
Intramuscular group (n = 10)
Day 7 60% (6) 10% (1) 20% (2) 10% (1) 0 0
Day 14 90% (9) 10% (1) 0 0 0 0
Subcutaneous group (n = 10)‡
Day 7 30% (3) 10% (1) 40% (4) 20% (2)
Day 14 44.4% (4) 33.3% (3) 11.1% (1) 11.1% (1) 0 0
Notes: *Defined as responders; †Scores from nine patients were available for day 14 (the score from the absent intramuscular patient was “much improved” on day 13); 
‡n = 9 on day 14 in the subcutaneous group (one patient discontinued the study); cgi-c was consistent with Pgi-c. There were more responders in the intramuscular 
treatment group but no statistically significant differences in the percentage of responders between the two groups (P = 0.335, two-sided Fisher’s exact test). 
Abbreviations: cgi-c, clinical global impression of change; Pgi-c, Patient global impression of change.
The EDSS scores, measuring level of disability, are 
reported in Table 5. As for the other assessments, there was 
some ability improvement in both the intramuscular and sub-
cutaneous treatment groups from visit 1 (baseline) to visit 3 
(day 14). However, as in the objective measures of function, 
the baseline EDSS scores are already highly functional. The 
median scores at baseline in this patient population ranged 
from 2.3 to 2.8, indicating “mild to moderate disability.”
In all, the subjective assessments of a shorter five-day 
course of treatment showed good patient response and toler-
ability, regardless of route of administration. In the objective 
assessments of function, patients generally improved after 
treatment. However, the low initial baseline scores suggest 
that this cohort of patients retained a high level of ability at 
study enrollment.
Patients from both treatment groups rated the study treat-
ment high for satisfaction, convenience, and tolerability on 
the drug attitude questionnaire on day 14 (Table 6). Of the 
seven patients (70%) in the intramuscular treatment group 
who reported experiencing pain associated with injection, 
all but one patient described the pain as mild. In contrast, 
only 33.3% of patients in the subcutaneous group reported 
injection site pain, all of whom described the pain as mild. Of 
note, 95% of study patients who completed the questionnaire 
(n = 18) reported that an injection at home was significantly 
more convenient than infusion in the clinic. Further, 90% of 
patients in the intramuscular group and 67% in the subcuta-
neous group said they would request the same intervention 
for any future acute exacerbations.
Safety and tolerability
Nineteen patients completed the study, and one patient in the 
subcutaneous group withdrew, citing lack of improvement. 
The injections were well tolerated by both treatment groups. 
Severe adverse events were reported in one intramuscular 
subject who complained of localized pain and numbness of 
0 = no
exacerbation
symptoms
10 = worst
exacerbation
symptoms
possible
Day 14
(LOCF)
Baseline
Mean improvement
A 2.5 6.3
0 = no
exacerbation
symptoms
10 = worst
exacerbation
symptoms
possible
Day 14
(LOCF)
Baseline
Mean improvement
B
2.9 4.3
Figure 3 Mean improvement on the visual analog scale in the iM (A) and Sc (B) 
groups.  comparable  improvement  of  the  symptoms  of  acute  exacerbation  was 
noted in both iM and Sc groups on the patient visual analog scale.
Abbreviations: LOcF, last observation carried forward; Sc, subcutaneous; iM, 
intramuscular.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 4 results of a timed walk and the nine-hole Peg Test (mean ± standard deviation)
Injection Mean timed walk (seconds) Nine-hole Peg Test (pegs/second)
Visit 1 Visit 2 Visit 3 Visit 1 Visit 2 Visit 3
intramuscular n = 10 
6.9 ± 2.4
n = 10 
6.3 ± 1.3
n = 10 
5.9 ± 1.2
n = 10 
14.7 ± 2.3
n = 10 
13.7 ± 2.8
n = 10 
13.8 ± 2.2
Subcutaneous n = 10 
7.3 ± 4.8
n = 10 
7.4 ± 5.1
n = 9 
8.1 ± 6.8
n = 10 
14.5 ± 3.5
n = 10 
14.0 ± 3.5
n = 9 
13.7 ± 3.2
the left hand and leg on one occasion and of the back and 
leg on another occasion. One subject in the subcutaneous 
treatment group had an ear infection. No serious adverse 
events were reported in either group.
Discussion
A recent comprehensive review of steroid hormone therapy 
for exacerbations of multiple sclerosis suggested that a 
short duration (five days) of methylprednisolone and a long 
duration (14 days) of ACTH appeared to have significant 
differences in treatment outcomes.7 We wanted to know if 
a short course of treatment (five days) using ACTH could 
still alleviate symptoms of an acute exacerbation of multiple 
sclerosis, and if patients liked the ACTH treatment protocol. 
In this small pilot study, we examined, for the first time, if a 
shorter, self-administered five-day course of ACTH therapy 
would show a treatment response.
In the literature, clinical trial data on the use of ACTH 
in acute exacerbations of multiple sclerosis come from two 
placebo-controlled, double-blind studies and one double-
blind comparator trial (ACTH versus methylprednisolone) 
involving a total of 298 subjects across all studies.3–5 In a 
study by Miller et al, ACTH gel was dosed 60 U intramus-
cularly twice daily in the first week, 40 U twice daily in 
the second week, and then 60 U, 40 U, and 20 U on days 
2, 4, and 6 of the third week.3 Rose et al dosed ACTH at 
40 U twice daily intramuscularly for seven days, tapered 
to 20 U twice daily for four days, and then 20 U daily for 
three days in their study.4 Thompson et al compared a regi-
men of intravenous methylprednisolone dosed 1 g/day for 
three days, with a 14-day course of ACTH given intramuscu-
larly as follows: 80 U/day for seven days, 40 U/day for four 
days, and 20 U/day for three days.5 A significant treatment 
effect of ACTH was demonstrated in the placebo-controlled 
studies, and no difference with methylprednisolone was 
reported in the small comparative study. Mild side effects 
were reported with ACTH and not methylprednisolone in 
the comparative study; it would be interesting to know if a 
Table 5 expanded disability status scale scores (mean ± standard 
deviation)
Injection Visit 1 
(baseline)
Visit 2  
(day 7 ± 1 day)
Visit 3  
(day 14 ± 1 day)
intramuscular n = 10 
2.30 ± 0.54
n = 10 
1.20 ± 0.95
n = 10 
1.10 ± 0.88
Subcutaneous n = 10 
2.80 ± 1.3
n = 10 
2.65 ± 1.38
n = 9 
2.89 ± 1.64
All n = 20 
2.55 ± 1.01
n = 20 
1.93 ± 1.37
n = 19 
1.95 ± 1.55
Table 6 responses to the drug attitude questionnaire on visit 3
Question Possible responses Intramuscular 
n (%)
Subcutaneous 
n (%)
Any pain associated with injection? no pain 
Mild pain 
Moderate pain 
Significant pain
3 (30) 
6 (60) 
1 (10) 
0
6 (67) 
3 (33) 
0 
0
Difficult to master the injection  
technique?
No difficulty 
Minimal difficulty 
Moderate difficulty 
Significant difficulty
7 (70) 
3 (30) 
0 
0
9 (100) 
0 
0 
0
injection at home more convenient  
than infusions in clinic?
Significantly more convenient 
Moderately more convenient 
Minimally more convenient 
no difference
10 (100) 
0 
0 
0
8 (89) 
0 
0 
1 (11)
Would you ask for this drug/route  
for an acute exacerbation?
Yes 
not sure 
no
9 (90) 
0 
1 (10)
6 (67) 
1 (11) 
2 (22)Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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shorter course of ACTH treatment would result in fewer side 
effects. No large studies have directly compared methylpred-
nisolone with ACTH in the treatment of acute exacerbations 
of multiple sclerosis.
The gel formulation of ACTH is approved by the Food 
and Drug Administration for several different indications, 
given either intramuscularly or subcutaneously.6 There are 
limited data available on the duration, dosing, and route 
of administration of ACTH gel in the treatment of acute 
exacerbations of multiple sclerosis. This pilot study is 
the first attempt to compare ACTH gel therapy administered 
either intramuscularly or subcutaneously. We found that 
patients in both the intramuscular and subcutaneous treat-
ment groups reported improvement in their condition after 
a five-day course of treatment with ACTH gel dosed at 
80 U/day. Improvement was also observed on the CGI-C 
scale, indicating that clinicians also observed meaningful 
improvements.
This was a pilot project and therefore had certain limita-
tions. Because of the small sample size, random assignment 
to treatment arms may not have eliminated bias entirely. In 
addition, because there was no control arm, it is unknown 
what percentage of exacerbations would have resolved spon-
taneously. It was difficult to measure improvement objectively 
in this study, because the patients demonstrated good func-
tion at enrollment and the study period was short (14 days). 
Lastly, while the drug attitude questionnaire showed general 
patient satisfaction with the ACTH treatment, the question-
naire failed to determine the sources of satisfaction, such as 
drug efficacy, tolerability, convenience, or cost. It will be 
important to address these issues in larger trials based upon 
the results of this small pilot study.
If confirmed, a shorter protocol for treatment of acute 
exacerbations with ACTH could have implications for disease 
management and clinical practice as it moves treatment from 
the clinic and hospital setting to the home, giving patients 
more control over their disease and improving their quality 
of life. Shortening the treatment time may lessen the cost of 
using ACTH while maintaining clinical efficacy and increas-
ing convenience to the patient, and changing the injection 
route from intramuscular to subcutaneous may minimize the 
pain and difficulty of treatment. Together, these elements of 
our modified protocol may decrease the burden of disease 
for the patient with multiple sclerosis, improve quality of 
life, and give physicians more patient-friendly options when 
treating acute exacerbations.
More clinical trials are needed to examine new dosing 
protocols with our “old” drugs as well as exploring drug 
combinations with the newer drugs available. However, the 
expense and time required for large, placebo-controlled 
studies can make this impractical. Small pilot studies may 
have value in such cases, where changes in drug protocol 
or special treatment protocols for patient subpopulations 
may be evaluated qualitatively and shared with the clinical 
community. In this way, we may be able to use the drugs we 
currently have more effectively.
Conclusion
Our study in 20 patients suggests that a five-day course of 
patient-administered ACTH gel therapy relieves symptoms 
of acute exacerbations of multiple sclerosis when adminis-
tered either as intramuscular or subcutaneous injections. In 
most cases, the patient’s lifestyle may be less disrupted by 
a self-administered injection compared with an infusion in 
the clinic, giving the patient more independence and control 
of their disease management. In addition, a shorter five-day 
course of treatment would reduce costs to the patient, in terms 
of drug cost, time, and the likelihood of adverse events. These 
results warrant further study of short-term, self-administered 
ACTH therapy for acute exacerbations of multiple sclerosis. 
Larger, placebo-controlled studies are needed to determine 
the optimal dose of ACTH gel, duration of treatment, and 
route of administration, as well as its role compared with 
steroid therapy.
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